0VQA Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Viking Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$52.81 |
| 52 Week High | US$99.30 |
| 52 Week Low | US$11.66 |
| Beta | 0.99 |
| 11 Month Change | -32.83% |
| 3 Month Change | -17.88% |
| 1 Year Change | 333.23% |
| 33 Year Change | 881.06% |
| 5 Year Change | n/a |
| Change since IPO | 257.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0VQA | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 4.7% | 0.3% | 2.2% |
| 1Y | 333.2% | -18.3% | 8.0% |
Return vs Industry: 0VQA exceeded the UK Biotechs industry which returned -18.3% over the past year.
Return vs Market: 0VQA exceeded the UK Market which returned 8% over the past year.
Price Volatility
| 0VQA volatility | |
|---|---|
| 0VQA Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0VQA's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0VQA's weekly volatility has decreased from 21% to 11% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 31 | Brian Lian | www.vikingtherapeutics.com |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.
Viking Therapeutics, Inc. Fundamentals Summary
| 0VQA fundamental statistics | |
|---|---|
| Market cap | US$5.86b |
| Earnings (TTM) | -US$99.15m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-59.1x
P/E RatioIs 0VQA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0VQA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$99.15m |
| Earnings | -US$99.15m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.89 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0VQA perform over the long term?
See historical performance and comparison